This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutEfficacyDosingSafety profileReal-world evidence

Information on how to access adverse event reporting can be found towards the bottom of the page.



Click here for Prescribing Information for CRESEMBA (isavuconazole)
Click here for Prescribing Infromation for VFEND (voriconazole)
CRESEMBA® (isavuconazole) - an antifungal triazole, is indicated for the treatment of:
• Invasive Aspergillosis1
• Mucormycosis in patients for whom amphotericin B is inappropriate.1
CRESEMBA® powder for concentrate for solution for infusion is indicated in patients from 1 year of age and above.
CRESEMBA® hard capsules are indicated in patients from 6 years of age and above.
Consideration should be given to official guidance on the appropriate use of antifungal agents.
Efficacy 

CRESEMBA® (isavuconazole) efficacy outcomes from the SECURE, VITAL and paediatric trials

More informationLoading
Dosing

Learn how CRESEMBA® (isavuconazole) allows for simple and reliable dosing 

More informationLoading
Safety

Read the details of the safety profile of CRESEMBA® (isavuconazole) including any contraindications, special warnings and precautions for use

More informationLoading
Real world evidence

Introducing PRISMA: an observational, retrospective, cohort study that provides additional evidence of the real-world effectiveness in routine clinical practice, in adults, in Europe, and safety profile similar to that obtained from clinical trial data of CRESEMBA®.2

Please note, observational retrospective analyses are not intended for direct comparison with clinical trials due to differences in study design and settings.

Find out how CRESEMBA® might help your patients in practice
LoadingPaediatric indication 

CRESEMBA® (isavuconazole) is the only azole approved for both invasive aspergillosis and mucormycosis in children as young as 1 year. 1,5-7

Click below to find out more about the paediatric indication

Efficacy
Loading
 Dosing 
LoadingReferences:CRESEMBA UK Summary of Product CharacteristicsNeofytos D, et al. Infect Dis Ther. 2024;13(12):2527–2543Maertens JA, et al. Lancet 2016;387(10020):760–769.Marty FM, et al. Lancet Infect Dis 2016;16(7):828–837.VFEND Summary of Product Characteristics. 2024.Noxafil Summary of Product Characteristics. 2023.Sporanox Summary of Product Characteristics. 2023.
PP-CRB-GBR-2690. August 2026

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2026 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-13934. January 2026
You are now leaving PfizerPro​​​​​
​
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-GBR-12070. April 2025​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-13971. December 2025

YesNo
You are now leaving PfizerPro

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

PP-UNP-GBR-12107. April 2025
​​​​​​​